Adjunctive and long-acting nanoformulated antiretroviral therapies for HIV-associated neurocognitive disorders

Howard Eliot Gendelman, Harris A. Gelbard

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose of review We are pleased to review current and future strategies being developed to modulate neuroinflammation while reducing residual viral burden in the central nervous system. This has been realized by targeted longacting antiretroviral nano and adjunctive therapies being developed for HIV-infected people. Our ultimate goal is to eliminate virus from its central nervous system reservoirs and, in so doing, reverse the cognitive and motor dysfunctions. Recent findings Herein, we highlight our laboratories' development of adjunctive and nanomedicine therapies for HIVassociated neurocognitive disorders. An emphasis is placed on drug-drug interactions that target both the viral life cycle and secretory proinflammatory neurotoxic factors and signaling pathways. Summary Antiretroviral therapy has improved the quality and duration of life for people living with HIV-1. A significant long-term comorbid illness is HIV-associated neurocognitive disorders. Symptoms, although reduced in severity, are common. Disease occurs, in part, through continued low-level viral replication, inducing secondary glial neuroinflammatory activities. Our recent works and those of others have seen disease attenuated in animal models through the use of adjunctive and long-acting reservoir-targeted nanoformulated antiretroviral therapy. The translation of these inventions from animals to humans is the focus of this review.

Original languageEnglish (US)
Pages (from-to)585-590
Number of pages6
JournalCurrent Opinion in HIV and AIDS
Volume9
Issue number6
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

HIV
Central Nervous System
Nanomedicine
Therapeutics
Life Cycle Stages
Viral Load
Drug Interactions
Neuroglia
HIV-1
Animal Models
Quality of Life
Viruses
Neurocognitive Disorders
Pharmaceutical Preparations
Cognitive Dysfunction

Keywords

  • HIV-associated neurocognitive disorders
  • Mixed lineage kinase
  • Nanoformulated antiretroviral therapy
  • Neuroinflammation

ASJC Scopus subject areas

  • Hematology
  • Oncology(nursing)
  • Immunology
  • Infectious Diseases
  • Virology
  • Oncology

Cite this

Adjunctive and long-acting nanoformulated antiretroviral therapies for HIV-associated neurocognitive disorders. / Gendelman, Howard Eliot; Gelbard, Harris A.

In: Current Opinion in HIV and AIDS, Vol. 9, No. 6, 2014, p. 585-590.

Research output: Contribution to journalArticle

@article{41958cc1bcfa4365b82fa2fb6a9fcbbf,
title = "Adjunctive and long-acting nanoformulated antiretroviral therapies for HIV-associated neurocognitive disorders",
abstract = "Purpose of review We are pleased to review current and future strategies being developed to modulate neuroinflammation while reducing residual viral burden in the central nervous system. This has been realized by targeted longacting antiretroviral nano and adjunctive therapies being developed for HIV-infected people. Our ultimate goal is to eliminate virus from its central nervous system reservoirs and, in so doing, reverse the cognitive and motor dysfunctions. Recent findings Herein, we highlight our laboratories' development of adjunctive and nanomedicine therapies for HIVassociated neurocognitive disorders. An emphasis is placed on drug-drug interactions that target both the viral life cycle and secretory proinflammatory neurotoxic factors and signaling pathways. Summary Antiretroviral therapy has improved the quality and duration of life for people living with HIV-1. A significant long-term comorbid illness is HIV-associated neurocognitive disorders. Symptoms, although reduced in severity, are common. Disease occurs, in part, through continued low-level viral replication, inducing secondary glial neuroinflammatory activities. Our recent works and those of others have seen disease attenuated in animal models through the use of adjunctive and long-acting reservoir-targeted nanoformulated antiretroviral therapy. The translation of these inventions from animals to humans is the focus of this review.",
keywords = "HIV-associated neurocognitive disorders, Mixed lineage kinase, Nanoformulated antiretroviral therapy, Neuroinflammation",
author = "Gendelman, {Howard Eliot} and Gelbard, {Harris A.}",
year = "2014",
doi = "10.1097/COH.0000000000000111",
language = "English (US)",
volume = "9",
pages = "585--590",
journal = "Current Opinion in HIV and AIDS",
issn = "1746-630X",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Adjunctive and long-acting nanoformulated antiretroviral therapies for HIV-associated neurocognitive disorders

AU - Gendelman, Howard Eliot

AU - Gelbard, Harris A.

PY - 2014

Y1 - 2014

N2 - Purpose of review We are pleased to review current and future strategies being developed to modulate neuroinflammation while reducing residual viral burden in the central nervous system. This has been realized by targeted longacting antiretroviral nano and adjunctive therapies being developed for HIV-infected people. Our ultimate goal is to eliminate virus from its central nervous system reservoirs and, in so doing, reverse the cognitive and motor dysfunctions. Recent findings Herein, we highlight our laboratories' development of adjunctive and nanomedicine therapies for HIVassociated neurocognitive disorders. An emphasis is placed on drug-drug interactions that target both the viral life cycle and secretory proinflammatory neurotoxic factors and signaling pathways. Summary Antiretroviral therapy has improved the quality and duration of life for people living with HIV-1. A significant long-term comorbid illness is HIV-associated neurocognitive disorders. Symptoms, although reduced in severity, are common. Disease occurs, in part, through continued low-level viral replication, inducing secondary glial neuroinflammatory activities. Our recent works and those of others have seen disease attenuated in animal models through the use of adjunctive and long-acting reservoir-targeted nanoformulated antiretroviral therapy. The translation of these inventions from animals to humans is the focus of this review.

AB - Purpose of review We are pleased to review current and future strategies being developed to modulate neuroinflammation while reducing residual viral burden in the central nervous system. This has been realized by targeted longacting antiretroviral nano and adjunctive therapies being developed for HIV-infected people. Our ultimate goal is to eliminate virus from its central nervous system reservoirs and, in so doing, reverse the cognitive and motor dysfunctions. Recent findings Herein, we highlight our laboratories' development of adjunctive and nanomedicine therapies for HIVassociated neurocognitive disorders. An emphasis is placed on drug-drug interactions that target both the viral life cycle and secretory proinflammatory neurotoxic factors and signaling pathways. Summary Antiretroviral therapy has improved the quality and duration of life for people living with HIV-1. A significant long-term comorbid illness is HIV-associated neurocognitive disorders. Symptoms, although reduced in severity, are common. Disease occurs, in part, through continued low-level viral replication, inducing secondary glial neuroinflammatory activities. Our recent works and those of others have seen disease attenuated in animal models through the use of adjunctive and long-acting reservoir-targeted nanoformulated antiretroviral therapy. The translation of these inventions from animals to humans is the focus of this review.

KW - HIV-associated neurocognitive disorders

KW - Mixed lineage kinase

KW - Nanoformulated antiretroviral therapy

KW - Neuroinflammation

UR - http://www.scopus.com/inward/record.url?scp=84924257481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924257481&partnerID=8YFLogxK

U2 - 10.1097/COH.0000000000000111

DO - 10.1097/COH.0000000000000111

M3 - Article

VL - 9

SP - 585

EP - 590

JO - Current Opinion in HIV and AIDS

JF - Current Opinion in HIV and AIDS

SN - 1746-630X

IS - 6

ER -